A publicly listed large pharma company in China is seeking strategic partnerships which can be in the form of licensing, equity, or acquisition of the asset. The firm’s typical investment depends on the technology, with a max investment of $10M – $15M per company. The firm is primarily seeking companies at growth and pre-IPO stages in fields of pharmaceuticals, biotechnology, and medical devices who have a strategic angle towards China. The firm invests in companies based in the U.S., China, Europe, and potentially South Korea and Israel.
The firm prioritizes biotechnology pharmaceuticals, with secondary interests in medical devices that produce high-value consumables and tertiary interests in diagnostic companies. The firm is not interested in companies that manufacture large medical equipment, such as MRI machines. For purely innovative technology, the firm will look as early as preclinical stage for those with high likelihood to succeed in clinics. In terms of indication, the firm prioritizes diabetes, cardiovascular, infectious disease, orthopedics, and oncology opportunities. However, the firm will look at indications outside of these areas.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment